Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents.
D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D000893:Anti-Inflammatory Agents; D000998:Antiviral Agents; D001249:Asthma / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000188:drug therapy; D006224:Cricetinae; D000242:Cyclic AMP / Q000032:analysis / Q000502:physiology; D006152:Cyclic GMP / Q000032:analysis / Q000502:physiology; D004194:Disease / Q000378:metabolism; D004789:Enzyme Activation; D005110:Extracellular Space / Q000032:analysis; D006162:Guanylate Cyclase / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents; D007527:Isoenzymes; D007700:Kinetics; D001523:Mental Disorders / Q000188:drug therapy; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy; D009765:Obesity / Q000188:drug therapy; D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D011565:Psoriasis / Q000188:drug therapy; D051381:Rats
D000893:Anti-Inflammatory Agents; D000998:Antiviral Agents; D007004:Hypoglycemic Agents; D007527:Isoenzymes; D010726:Phosphodiesterase Inhibitors; D000242:Cyclic AMP; D010727:Phosphoric Diester Hydrolases; D000262:Adenylyl Cyclases; D006162:Guanylate Cyclase; D006152:Cyclic GMP